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Abstract
Background: The 2014/2015 Ebolavirus outbreak resulted in more than 28,000 cases and 11,323 reported deaths, as
of March 2016. Domestic transmission of the Guinea strain associated with the outbreak occurred mainly in six
African countries, and international transmission was reported in four countries. Outbreak management was limited
by the inability to rapidly diagnose infected cases. A further fifteen countries in Africa are predicted to be at risk of
Ebolavirus outbreaks in the future as a consequence of climate change and urbanization. Early detection of cases
and reduction of transmission rates is critical to prevent and manage future severe outbreaks. We designed a rapid
assay for detection of Ebolavirus using recombinase polymerase amplification, a rapid isothermal amplification
technology that can be combined with portable lateral flow detection technology. The developed rapid assay
operates in 30 min and was comparable with real-time TaqMan™ PCR.
Methods: Designed, screened, selected and optimized oligonucleotides using the NP coding region from Ebola
Zaire virus (Guinea strain). We determined the analytical sensitivity of our Ebola rapid molecular test by testing
selected primers and probe with tenfold serial dilutions (1.34 × 1010− 1.34 × 101 copies/μL) of cloned NP gene from
Mayinga strain of Zaire ebolavirus in pCAGGS vector, and serially diluted cultured Ebolavirus as established by real-
time TaqMan™ PCR that was performed using ABI7500 in Fast Mode. We tested extracted and reverse transcribed
RNA from cultured Zaire ebolavirus strains – Mayinga, Gueckedou C05, Gueckedou C07, Makona, Kissidougou and
Kiwit. We determined the analytical specificity of our assay with related viruses: Marburg, Ebola Reston and Ebola
Sudan. We further tested for Dengue virus 1–4, Plasmodium falciparum and West Nile Virus (Kunjin strain).
Results: The assay had a detection limit of 134 copies per μL of plasmid containing the NP gene of Ebolavirus
Mayinga, and cultured Ebolavirus and was highly specific for the Zaire ebolavirus species, including the Guinea strain
responsible for the 2014/2015 outbreak. The assay did not detect related viruses like Marburg, Reston, or Sudan
viruses, and other pathogens likely to be isolated from clinical samples.
Conclusions: Our assay could be suitable for implementation in district and primary health laboratories, as only a
heating block and centrifuge is required for operation. The technique could provide a pathway for rapid screening
of patients and animals for improved management of outbreaks.
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Background
The Ebolavirus outbreak dominated international news
in 2014 and the World Health Organization reported
more than 28,000 cases worldwide and over 11,000
deaths [1]. After the initial outbreak in Guinea in
December 2013 [2], there was intense and wide-spread
transmission to neighbouring countries including Sierra
Leone and Liberia. The virus was also exported to Mali,
Nigeria, Senegal, the United States of America, and
Europe [3, 4] Transmission was drastically reduced after
global intervention, and all the affected countries have
been declared “Ebola free” and travel restrictions have
been lifted [5]. Nonetheless, 15 countries in Africa are
predicted to be at risk of Ebolavirus outbreaks [6], based
on the proximity of people to animals that harbour the
virus, as well as environmental factors including climate
change and urbanization. The Freetown Declaration on
the 16th of October 2015 at the end of the Ebola out-
break in Sierra Leone called for action against the re-
emergence of Ebolavirus, including the improvement of
laboratory facilities for early detection [7]. The most
recent reported Ebolavirus disease (EVD) outbreak, in
July 2017 in the Democratic Republic of Congo, with 5
laboratory confirmed cases and 4 deaths [8] further
stresses the importance of action in the diagnostic space.
Early laboratory diagnosis is pivotal for the prevention
of re-emergence of Ebolavirus. Current laboratory diag-
nosis includes real-time polymerase chain reaction (RT-
PCR), antigen-capture enzyme-linked immunosorbent
assay (ELISA), immunoglobulin M (IgM) and immuno-
globulin G (IgG) ELISA [9–16]. Additionally, there have
been recent Ebolavirus assay developments using anti-
body and antigen detection and isothermal amplification
technologies [17–20]. The assays deployed during the
last Ebola outbreak were a combination of antigen-
antibody-based and nucleic acid tests: RealStar Zaire
Ebolavirus RT-PCR Kit (Altona Diagnostics, Hamburg,
Germany); GeneXpert® Ebola Assay (Cepheid, Sunnyvale,
California, USA), FilmArray® BioThreat/Ebola Panels
(BioFire, Salt Lake City, Utah, USA); ReEBOV Antigen
Rapid Test (Corgenix, Broomfield, Colorado, USA); SD
Q Line Ebola Zaire Ag test (SD Biosensor, Suwon,
Gyeonggi-do, Republic of Korea). The deployment of
these assays depended on laboratory capabilities, rapid
turn-around and easy use of the Ebolavirus test device.
However, these assays did not consider any future detec-
tion of the virus; a future Ebolavirus outbreak has been
predicted to affect 15 countries in Africa [6]. Addition-
ally, the molecular assay results are not compatible with
clinical laboratories that lack PCR expertise and infra-
structural requirements, making the assays less relevant
to technicians in resource-limited settings. Detection of
viral RNA has proven to be most effective for diagnosis
of Ebolavirus infections from the early to late stage of
illness, however the standard RT-PCR Ebola assay is not
readily available in areas where it is most needed.
Among the isothermal technologies developed [21–30],
recombinase polymerase amplification (RPA) appears
very amenable to resource limited settings [28, 31]. The
technology is fast, amplifying nucleic acids in 10 min, and
can operate at body temperature or even lower (22 °C to
38 °C) [32]. The sensitivity and specificity of RPA is
comparable to PCR, and is amenable to all PCR-derived
amplification detection strategies including, real-time
fluorescence and lateral flow strips (LFS) [31]. RPA has
previously been reported for the detection of several RNA
viruses, including Middle East respiratory syndrome cor-
onavirus, Rift Valley fever virus, Ebolavirus and several
filoviruses. These viruses were detected using portable
fluorescent equipment, a real-time procedure [32–40].
Here we describe a rapid, sensitive, and specific assay for
Zaire ebolavirus, which includes the current Guinea
strain. Our assay uses RPA, but rather than using real-
time fluorescent imaging, the assay uses the LFS as a
detection format, making results very simple to interpret.
A similar approach has also been used in the detection of
RNA viruses such as Yellow fever virus [41] and Chla-
mydia trachomatis diagnosis [42]. The LFS component of
the test (Milenia Biotec, Giessen, Germany) is designed to
detect an RPA amplicon dual-labelled with FAM and bio-
tin (supplied in the RPA primers and probes and incorpo-
rated during the amplification step). The amplicon is
captured by gold-nanoparticles labelled with FAM-specific
antibodies in the sample application area, before travers-
ing to immobilized anti-biotin antibodies bound at a test
line; precipitation of the gold nanoparticles at the test line
results in the appearance of a red-blue band. Excess gold
nanoparticles are also captured by species-specific anti-
bodies bound to a control line; appearance of a red-blue
band in the control line confirms correct operation of the
strips in the absence of dual-labelled amplicon.
Our assay using the RPA-LFS method is highly amen-
able for low-resource laboratory, and has the potential
to be deployed in future Ebolavirus outbreaks. The aim
of this study was to develop an assay that is comparable
and faster than RT-PCR with easy to interpret results.
Additionally, we sought an assay that could be easily de-
ployed in an outbreak situation, where limited resources
preclude PCR laboratory facilities.
Methods
Sample preparation
Ebolavirus strains and related viruses (Table 1) were
grown on Vero E6 cells and harvested from infected cell
culture supernatant after centrifugation at 12,000 g. Stocks
determined to have > 106 PFU/mL by standard plaque
assay were used for RNA extraction (140 μL) using an
RNeasy Mini Kit (QIAGEN, Australia) according to the
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manufacturer’s instructions. All the procedures and
manipulation of Ebolavirus-infected cultures were per-
formed in a Biosafety Level 4 Laboratory at the CSIRO
Australian Animal Health Laboratory. All samples were
eluted in 50 μL nuclease free water, and 5 μL was used
in a 20 μL reverse transcription reaction. Reverse tran-
scription was performed using SuperScript IV Reverse
Transcriptase (Thermo Fisher Scientific, MA, USA)
and random hexamers (Thermo Fisher Scientific, MA,
USA) according to manufacturer’s instructions, and 5 μL
resultant cDNA was used as template for RPA-LFS.
Dengue 1–4 and West Nile virus (Kunjin NSW 2011
strain) RNA extractions were a gift from Professor Roy
Hall (University of Queensland, Brisbane, QLD, Australia)
and Plasmodium falciparum (malaria) genomic DNA was
a gift from Prof James McCarthy (QIMR-Berghofer,
Brisbane, QLD, Australia).
Ebola RPA assay
Primers and probes were synthesized by Integrated DNA
Technology (Iowa, USA), and purified by standard
desalting. Assays were first optimised using synthetic
gene fragments of one of the isolates (Accession num-
ber; KJ660348.1), from 470 to 2210 bp (1794 bp) as a
template (data not shown). Optimal primers EBZ#3F (5’
TCT CGT CCT CAG AAA GTC TGG ATG ACG
CCG) and EBZ#3R (5’ Biotin-TAC TTG ATA CAC
TGG GAT GAC TCT TTG CCG) and probe EBZ#3P
(5’ FAM-CTY ACT GAA TCT GAC ATG GAT TAC
CAC AAG ATC /idSp/TR ACA GCA GGT CTG TCC
/3SpC3/) amplified a 132 base pair fragment of the
Ebolavirus Makona (Guinea) strain (Accession number
KJ660348.1, amplification occurred between nucleotides
476 and 608). The Ebola RPA assay was performed using
the TwistAmp™ nfo kit in pellet format (TwistDx,
Cambridge, United Kingdom) according to manufacturer’s
instructions, but with modification to the primers and
probe concentrations and final volume. Briefly, 29.5 μL of
rehydration buffer was mixed with 2.1 μL of each forward
and reverse primer (10 μM) and 0.6 μL of the target spe-
cific probe (10 μM). Then 34.3 μL of this master mix was
added to the dry reagent pellet, followed by 5 μL of the
template, and the pellet resuspended by aspirating and
dispensing several times. The reaction was activated by
addition of 2.5 μL magnesium acetate (280 mM) to the
reaction mix, followed by incubation at 37 °C for 30 min.
After amplification, 1 μL of the amplified product was di-
luted with 9 μL of running buffer (Milenia Biotec, Giessen,
Germany) and added to the sample pad of the HybriDe-
tect lateral flow strip (Milenia Biotec, Giessen, Germany).
Strips were placed into tubes containing 100 μL of run-
ning buffer for 5 min, and photographed using a digital
camera. Grey-scale converted images were analysed using
ImageJ software (National Institutes of Health, MD, USA)
to determine band-intensity, by measuring the mean grey
value (limit to threshold), using a fixed area measurement,
and subtracting from the maximum grey value (255). For
each test band, the average of two neighbouring white
spaces was subtracted from the band intensity to
normalize the results. A sample was defined as positive if
the normalised band intensity was 1.3 times higher than
the standard deviation of the two neighbouring white
space values.
Determination of analytical sensitivity and specificity
Following similar viral RNA assay development studies
that employed RPA technology in establishing limit of
detection using cloned gene [34, 35], we also performed
standard ten-fold dilutions of an in-vitro synthesis (Gen-
script, USA) of the Zaire ebolavirus NP gene (Kikwit
isolate) cloned into EcoRI/XhoI sites of pCAGGS. These
pCAGGS were tested in two replicates using real-time
TaqMan PCR with previously described Ebolavirus
species specific primers and probe [43]. The assay was
performed using SuperScript III Platinum Taq One-Step
quantitative PCR Kit (Thermo Fisher Scientific, MA,
USA) and the ABI7500 in Fast Mode. The plasmid
dilutions were subsequently tested with RPA-LFS for
Table 1 Ebolavirus strains and related viruses used for RT-RPA-LFS assay
Filovirus Species Ebolavirus strain Accession Number Origin Date
Zaire ebolavirus Mayinga AF086833.2 Zaire 1976
Zaire ebolavirus Kikwit KR867676.1 Zaire 1995
Zaire ebolavirus Kissidougou KJ660346.1 Guinea 2014
Zaire ebolavirus Makona KJ660347.2 Guinea 2014
Zaire ebolavirus Makona-Gueckedou C05 KJ660348.1 Guinea 2014
Zaire ebolavirus Gueckedou C07 KJ660347.1 Guinea 2014
Related virus
Marburg marburgvirus Marburg virus Ravn EF446131 Kenya 1987
Reston ebolavirus Reston virus FJ621585 Philippines 2008
Sudan ebolavirus Sudan virus - Boniface AY729654 Uganda 2000
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determination of analytical sensitivity. Related Ebola-
viruses (Table 1) and Dengue 1–4, Plasmodium falcip-
arum, West Nile virus were also tested with RPA-LFS for
determination of the analytical specificity of the assay.
Results
Establishing the RPA-LFS assay
Zaire ebolavirus species specific RPA primers and
probes were designed based on the published sequence
of the Guinea strain (Accession number; KJ660348.1)
with the use of PRIMER-BLAST [44], which generated
20 nucleotides that were extended manually to a longer
30 nucleotides to be more amenable for RPA reactions.
The sequences of the selected primers and probes were
compared with an alignment of the NP gene sequences
of seven isolates of the virus (Accession number;
AF086833.2, KC242785.1, KC242796.1, KC242800.1,
KC242792.1, KJ660346.1, KJ660347.1) to confirm hom-
ology with thee strains, which represented the various
human outbreaks between 1976 and 1995 and the
2014 outbreak [2, 45–47]. Labelled primers and probes
were tested for RPA followed by LFS detection (Zaire
RPA-LFS) using a synthetic Ebolavirus template, and
tested for optimal reaction times between 5 to 40 min.
The optimal reaction time at 37 °C was 30 min, plus
5 min incubation of the LFS in the running buffer. A
visible red colour band at the control and test lines
were observed for positive controls while the no tem-
plate control (negative control) had only one band at
the control region of the strip. The control band on
both strips indicated a valid RPA-LFS assay.
Analytical sensitivity and specificity of the RPA-LFS assay
The detection threshold of the Zaire RPA-LFS was de-
termined using a dilution series of plasmid containing
the NP gene (1.34 × 1010 to 1.34 × 101) copies / μL), and
viral RNA from cultured Ebolavirus and comparing
results to quantification using the gold standard real-
time PCR assay. Detection using Zaire RPA-LFS showed
the same sensitivity to RT-PCR, with a detection limit of
1.34 × 102 copies / μL (Fig. 1) and was notably faster
(30 min versus > 2 h). We note that a faint band was
sometimes observed in no template negative controls,
however, this faint band was clearly distinguishable from
a b c d
Fig. 1 Analytical sensitivity of Ebolavirus RPA-LFS test. Sensitivity testing using both plasmid containing the Ebolavirus gene (top) and Zaire
Ebolavirus RNA (bottom). a RT-PCR cycle threshold (Ct) values for a single sample, along with corresponding photograph of LFS with control
bands (all samples) and test bands (positive samples) compared to copy number of serially diluted template DNA or RNA (copies/μL) and no
template control. b Normalised pixel density (black values) from the assay displayed in (a). c Positive results compared to number of runs tested
at that dilution. d Analytical sensitivity displayed as percentage of correct results from all runs. The test line appeared at every dilution down to
102 copies/μL, which was comparable with Real-Time PCR
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true positives, as demonstrated by ImageJ analysis of
black pixel density. Such image analysis could be
performed in field situations through the use of a lateral
flow reader. We note that the faint test bands in the no
template negative controls and Fig. 2 have been shown
to disappear using higher dilutions of RPA product in
the lateral flow device (e.g. 1:100–1:200) [48] compared
to the 1:10 dilution that we used, however, this may
affect sensitivity of the assay. We also observed that in
the case of very high concentrations of hybridization
product, the intensity of the control band was affected,
but this did not affect interpretation of results.
In order to determine cross reactivity or analytical spe-
cificity of our assay, we tested cultured viral RNA from
Reston, Sudan and Marburg viruses, as well as different
strains of Zaire ebolavirus species (Table 1). Marburg
viruses show the same haemorrhagic symptoms as Ebo-
laviruses and Ebola cases were mistaken for Marburg
virus when it was first discovered in 1976 [46]. We also
tested Plasmodium falciparum, Dengue virus 1–4 and
West Nile virus (Kunjin NSW 2011 strain), as these
pathogens are likely to be isolated from clinical samples
in the same geographic region. Our Zaire ebolavirus
RPA-LFS did not show a positive test result when ex-
posed to the Marburg RNA, any of the other ebolavirus
species, or other pathogens (Fig. 2), indicating the assay
was specific to Zaire ebolavirus species. We confirmed
this specificity by demonstrating a test line consistently
appeared when exposed to viral RNA from cultures of
different Zaire ebolavirus strains (Fig. 3).
Discussion
Reliable and rapid diagnosis of patients suspected of
having EVD is critical to prevention, limiting the spread
and management of treatment. This need was clearly
made apparent in the Freetown declaration, which was a
collective response to the Ebolavirus outbreak that killed
more than 11,000 people, made by delegates from the
African Society for Laboratory Medicine and the World
Health Organisation in Freetown, Sierra Leone, in Octo-
ber 2015. The declaration included a strong call to build
and strengthen laboratory networks to prevent, detect
a b c d
Fig. 2 Specificity of the Ebolavirus RPA-LFS test. a Representative photograph of LFS with control bands and test bands of different viral isolates,
Plasmodium falciparum, positive control genomic template DNA, or no template control. b Normalised pixel density (black values) from the test
displayed in (a). c Positive results of all test runs compared to number of individual runs. d Specificity displayed as percentage of correct results
from all runs
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and respond to new and future diseases threats [7].
Importantly, innovative diagnostic tools that are compar-
able to current gold standards for resource-limited set-
tings have been identified as critical to EVD diagnosis.
In particular, a major challenge with RT-PCR is its
inappropriateness for settings where there is lack of ex-
pertise and infrastructure to support its implementation.
Typically, PCR facilities are many miles away from dis-
trict hospitals where they are critically needed. Hence,
suspected EVD samples sent to central facilities can take
two or more days before the patients are aware of their
status. This delay has major impacts on patient isolation,
care and treatment.
In the very active space of Ebola diagnostics post the
2014 outbreak, the challenge still remains to develop a
rapid, sensitive, selective Ebolavirus test, and to undergo
full regulatory assessment and field testing. Tests for
IgM/IgG [49, 50] cannot detect early-stages of the dis-
ease before patients have mounted an immune response.
Antibody-based diagnostics detecting Ebolavirus anti-
gens like ReEBOV Antigen Rapid Test (Corgenix,
Broomfield, Colorado, USA); SD Q Line Ebola Zaire Ag
test; (SD Biosensor, Suwon, Gyeonggi-do, Republic of
Korea); Ebola (Senova Immunoassay Systems, Weimar,
Germany); OraQuick Ebola Rapid Antigen Test (Ora-
Sure Technologies, Bethlehem, Pennsylvania, USA) are
reasonably easy to operate and offer rapid on-site detec-
tion incorporating small quantities of blood or serum as
material. However, these antibody based diagnostic
methods are not as sensitive as their RT-PCR test coun-
terparts. Thus, currently used reference assays solely
detect viral RNA, such as the RealStar Filovirus Screen
RT-PCR Kit 1.0 and its improved RealStar Zaire Ebola-
virus RT-PCR Kit version, Altona Diagnostics. These
RT-PCRs were originally designed for research only and
hence mostly include labour-intensive RNA extraction
steps, temperature-sensitive reagents, expensive labora-
tory equipment and the need for manual read-out.
Therefore, highly trained staff are making multiple preci-
sion steps in sophisticated high containment laboratories
to deliver an EVD result with a turnaround time from
four to 6 h. In contrast, an automated system integrates
sample purification, nucleic acid amplification and de-
tection of the target sequence using RT-PCR, addition-
ally lowering the risk for technical personnel. A verified
example of an automated system is the GeneXpert®
System combined with the Xpert® Ebola Assay
(Cepheid, Sunnyvale, California, USA), able to deliver
results in ~ 2.5 h. Other companies have also designed
automated or semi-automated Ebola assays (Idylla™
EBOV test (Biocartis, Mechelen, Belgium); BioThreat/
Ebola Panels (BioFire, Salt Lake City, Utah, USA) for
point-of-care; these systems tend to be easily portable
(7.8 to 25.2 kg) but come with a high price tag.
In contrast, here we report a molecular assay for Zaire
ebolavirus species detection using a LFS, and only requiring
simple and inexpensive equipment (such as a 37 °C heating
block and lateral flow reader). The assay is simple, fast,
comparable with the current gold standard, and reduces
the infrastructural requirements and technical needs com-
monly associated with the RT-PCR-based assays. Our assay
has the same detection limit as PCR (Fig. 1) and was highly
specific for the Zaire ebolavirus strains, which have been
responsible for different outbreaks since 1976 as well as the
recent outbreak (Figs. 2 and 3). The assay employs a novel
isothermal amplification technology, RPA, which has previ-
ously been applied for the detection of DNA and RNA
organisms [31]. Our assay sensitivity and specificity are
similar to previously published studies using RPA for the
detection of RNA viruses [32–40].
a b c d
Fig. 3 RPA-LFS detection of Zaire ebolavirus strains. a Photograph of LFS with control bands and test bands of different Zaire ebolavirus strains,
positive control (1.34 × 106 copies/μL synthetic template DNA) or no template control. b Normalised pixel density (black values) from the assay
shown in (a). c Positive results compared to number of individual runs. d Specificity displayed as percentage of correct results
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RPA is yet to demonstrate its potential in the detection
of nucleic acids directly from clinical samples, apart
from urine [42]. For blood testing, it is anticipated that
RNA extraction would need to be performed first, pos-
sibly using rapid methods that do not require centri-
fuges, such as the SpeedXtract Nucleic Acid Kit, with a
15 min extraction protocol and requires only 20 μL of
blood serum (Qiagen Hilden, Germany) [51, 52]. This
nucleic acid kit was deployed in combination with a
prototype diagnostic that employs real time version of
RPA during the recent Ebolavirus outbreak and is based
on a magnetic particle technology that removes inhibi-
tors [52]. Similarly, although we used a two-step reverse
transcription approach in sample preparation, for field
detection a one-step method could be used as demon-
strated previously by RPA-detection of Rift Valley fever
virus [35], where MuLV reverse transcriptase was in-
cluded in the RPA reaction pellets, making the cDNA
synthesis step easier and amenable to resource-limited
settings. In addition, a disposable detection device that
allows the assay to be performed in a closed system
could be used to prevent cross-contamination of sam-
ples, contain the spread of amplified products, and pro-
tect the operator during the procedure [53]. We note
that previous RPA assay publications have indicated a
constant shaking speed is required for a more stable
signal on the strip, and that agitation also improves
sensitivity and amplification time, particularly when the
detection limit is low [42]. However, our RPA was per-
formed without agitation and yet achieved similar sensi-
tivity to RT-PCR. We chose to ignore the shaking event,
because in a typical routine diagnostic laboratory this
step might be forgotten or omitted as a result of sched-
uled turnaround time with other routine diagnostic as-
says or work load. It is possible that with shaking our
sensitivity may have been even more improved and
could reduce the reaction time below 30 min.
Our RPA-LFS for Zaire ebolavirus species, as a quali-
tative assay, when combined with the technologies for
rapid low-resource detection described above, could pro-
vide a rapid response to Ebolavirus outbreaks in the fu-
ture. The cost of components is approximately USD $10
per test, without the sample preparation step. In the
2014/2015 Ebolavirus outbreak over 28,000 cases were
diagnosed. If another epidemic were to build with a
similar scale, it is critical to take space limitations in
high-containment facilities into consideration. Therefore,
complete inactivation of Ebolavirus samples is essential
to allow specimens to be manipulated outside of bio-
logical contained facilities. Currently, our test system
requires RNA extraction with a commercially available
kit. However, this step may be easily replaced by the use
of TRIzol® LS reagent (Invitrogen Corp., Carlsbad, CA),
which successfully inactivates members of the Filovirus
species [54]. This would enable the assay to be per-
formed outside of a high containment facility, accelerat-
ing turnaround time to diagnose an EVD case. However,
replacing the labour-intensive low-throughput RNA
isolation with either a safe, low-cost, high-throughput
version, or eliminating RNA extraction completely, is
still highly desirable. Such an optimised Ebolavirus test
version could have high potential to be compatible with
unprocessed clinical material, such as whole blood ob-
tained by finger-stick. Indeed, Clancy and colleagues
(2015) have successfully shown the detection of Strepto-
coccus pneumoniae with whole blood as material using
an isothermal amplification approach by RPA [55]. A
field trial of our Ebolavirus test or an optimized version
during an Ebolavirus outbreak is essential. Yet, it is im-
possible to predict the strain that future outbreaks may
be caused by. Our primers and probe may also detect
these future strains because the genetic diversity within
the Ebolavirus (particularly Zaire ebolavirus species) has
been very low to date, with a maximum of 2.7% nucleo-
tide difference between sequences [56]. This minimal
diversity is also evident with the Guinea strain which
showed 97% identity with previous strains [2]. Addition-
ally, the designed oligonucleotides that utilized the
Guinea strain, detected previous strains, demonstrating
a versatility that may help detect future strains. Similar
assays could be designed to detect other Filovirus species
responsible for outbreaks.
Conclusion
We have developed an Ebolavirus assay that could be
implemented in low-resource laboratories that do not
have the capacity for RT-PCR, and this assay could po-
tentially be helpful in the next outbreak. However, field
evaluation of the assay in a typical clinical setting will
help to determine clinical sensitivity and specificity
respectively, and areas of improvement.
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